Sanofi - Aventis Groupe: Press Release: New nirsevimab data

New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory

Related Keywords

Paris , France General , France , Athens , Attikír , Greece , Japan , United Kingdom , Philadelphia , Pennsylvania , United States , China , California , Eva Schaefer Jansen , Nicolas Obrist , Corentine Driancourt , Peric Sim , Felix Lauscher , Kate Conway , Nathalie Pham , Sandrine Guendoul , Sally Bain , Priya Nanduri , Nasdaq , European Society For Paediatric Infectious Diseases , Global Head Of Research , Astrazeneca , California Perinatal Association , Burden Of Community , Japan Agency For Medical Research , China Center , Centers For Disease , Drug Administration , Regulatory Agency , Uc Denver School Of Medicine , National Medical Products Administration , European Medicines Agency Ema Priority , Development Vaccines , Euronext , European Society , Paediatric Infectious Diseases , Pediatrics Infectious Diseases , Vice President , Annual Meeting , Collaboration Revenue , Breakthrough Therapy Designation , Drug Evaluation , European Medicines Agency , Promising Innovative Medicine , United Kingdom Medicines , Drug Selection , Promote New Drug Development , Japan Agency , Medical Research , New England Journal , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Healthy Late , Single Dose Nirsevimab , Medically Attended , Healthy Late Preterm , Term Infants , Accessed May , Healthy Preterm , Medically Attended Respiratory Syncytial Virus , Lower Respiratory Track Infection , Disease Control , California Perinatal , Sanofi , Eventis , Roupe , Dress , Release , Nirsevimab , Data , Analyses , Reinforce , Efficacy , Against ,